Amgen names Sean Bruich chief technology officer as David Reese retires

Amgen Inc.

Amgen Inc.

AMGN

0.00
  • Amgen set retirement of Executive Vice President, Chief Technology Officer David M. Reese effective June 30, 2026.
  • Management changes effective June 1, 2026 shift James Bradner to Executive Vice President, Research and Development, Artificial Intelligence and Data; he is a physician-scientist focused on biology-technology integration.
  • Sean Bruich named Senior Vice President, Chief Technology Officer; he has led Amgen AI and data capability buildout across technology and data science.
  • Murdo Gordon moved to Executive Vice President, Amgen Global Markets and Policy, covering medical, commercial operations, government affairs and policy; he has led global markets and policy work with health systems and clinicians.
  • Paul Burton continues as Senior Vice President, Chief Medical Officer, maintaining focus on clinician and patient engagement across priority disease areas.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604221600PR_NEWS_USPR_____LA41220) on April 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.